| On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO | Sarah de Crescenzo | 07/06/20 | San Francisco |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients | Sarah Karlin-Smith | 07/02/20 | National |
| BioNTech’s mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity | Frank Vinluan | 07/01/20 | Europe |
| Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s | Frank Vinluan | 07/01/20 | Boston |
| Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases | Sarah de Crescenzo | 07/01/20 | Boston |
| Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later | Frank Vinluan | 06/30/20 | Boston |
| FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data | Frank Vinluan | 06/29/20 | New York |
| Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More | Sarah de Crescenzo | 06/26/20 | National |
| CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy | Frank Vinluan | 06/25/20 | Philadelphia |
| Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs | Sarah de Crescenzo | 06/25/20 | Boston |
| La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War | Frank Vinluan | 06/24/20 | San Diego |
| Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds | Sarah de Crescenzo | 06/22/20 | Boston |
| Diversity & Inclusion Events Have Halted. Our Conversations Shouldn’t. | Ramsey Johnson | 06/22/20 | Boston |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo | Sarah de Crescenzo | 06/19/20 | Boston |
| Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs | Sarah de Crescenzo | 06/18/20 | San Diego |
| Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies | Frank Vinluan | 06/17/20 | San Francisco |
| Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer | Sarah de Crescenzo | 06/17/20 | San Diego |
| C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic | Sarah de Crescenzo | 06/16/20 | Boston |
| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Akili Interactive’s Video Game for ADHD Gets the FDA All Clear | Frank Vinluan | 06/15/20 | Boston |
| FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19 | Sarah de Crescenzo | 06/15/20 | National |
| GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track | Mandy Jackson | 06/12/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia | Frank Vinluan | 06/11/20 | Boston |
| Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine | Frank Vinluan | 06/11/20 | Boston |
| Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes | Frank Vinluan | 06/11/20 | Boston |
| Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition | Frank Vinluan | 06/09/20 | New York |
